DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Arizona Cancer Center
Tucson, Arizona, United States
- Cedars-Sinai Medical Center
Los Angeles, California, United States
- Usc/norris Comprehensive Cancer Center
Los Angeles, California, United States
- University of Colorado Cancer Center
Aurora, Colorado, United States
- Intermountain
Golden, Colorado, United States
- Yale Cancer Center
New Haven, Connecticut, United States
- Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
- Louisiana State University Health Sciences Center- New Orleans
New Orleans, Louisiana, United States
- Cancer Partners of Nebraska
Lincoln, Nebraska, United States
- New Mexico Cancer Care Alliance
Albuquerque, New Mexico, United States
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
- Stony Brook University Cancer Center
Stony Brook, New York, United States
- the Ohio State University Wexner Medical Center James Cancer Hospital
Columbus, Ohio, United States
- Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
- Oregon Health and Science University
Portland, Oregon, United States
- Prisms Group
Laredo, Texas, United States
- Virginia Cancer Institute
Richmond, Virginia, United States
- Swedish Cancer Institute
Seattle, Washington, United States
- University of Wisconsin Clinical Science Center
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Feb 2021
- Primary completion
- 31 Dec 2027
- Completion
- 31 Dec 2028
- Last update posted
- 8 Jul 2026
- Registered enrollment
- 70
- Registry id
- NCT04567420
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.